ClinicalTrials.gg
CompletedNCT06525935Updated Oct 5, 2026

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

A Phase 2 interventional study of Placebo and Enicepatide in Obesity and Overweight, sponsored by Carmot Therapeutics, Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
469
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Enrollment
8th of 21
469 · median 300
Started
2024
with 1 other
Phase 2
7 of 21
1 open now
Registered
7th of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 8th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 75 years of age
  • (BMI) ≥30.0 kg/m2, OR BMI ≥27.0 and \<30.0 kg/m2 and previously diagnosed with at least 1 of the following weight-related comorbidities, such as: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
  • At least one self-reported unsuccessful effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • Prior history/diagnosis/lab evidence of any type of diabetes mellitus (e.g., Type 1, Type 2, gestational), or a history of ketoacidosis or hyperosmolar state
  • Self-reported body weight change of >5 kg within 3 months before randomization
  • Any unbalanced/extreme diets within 3 months of the screening visit, or plan to be on such diets during the study
  • Current or recent participation in an organized weight reduction program
  • Current or recent use of any treatment that promotes weight loss or glucose metabolism
  • Current or recent use of treatment that may cause weight gain
  • Prior or planned surgical treatment for obesity
  • or active gastric emptying abnormality, malabsorption, or chronic use of medications that directly affect GI motility
  • History of chronic pancreatitis or acute pancreatitis within 6 months before screening
  • Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
  • History of major depressive disorder within 2 years of screening, or any history/diagnosis of other severe psychiatric conditions (Note: Prospective participants with depression or anxiety whose disease state, in the opinion of the Investigator, is considered stable and expected to remain stable throughout the course of the study, may be considered for inclusion)
  • Family or personal history of medullary thyroid carcinoma
  • Serum calcitonin ≥ 20 ng/L
  • Women who are pregnant, breastfeeding, or intend to become pregnant, or are of and not using a highly effective method
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
469 participants (actual)

Study arms

  • Placebo comparator
    Arm 1: Placebo

    Placebo administered subcutaneously (SC) once weekly.

    Drug: Placebo

  • Experimental
    Arm 2: Enicepatide Dose Level 1 (Low)

    Enicepatide Dose Level 1 administered SC once weekly.

    Drug: Enicepatide

  • Experimental
    Arm 3: Enicepatide Dose Level 2

    Enicepatide Dose Level 2 administered SC once weekly.

    Drug: Enicepatide

  • Experimental
    Arm 4: Enicepatide Dose Level 3

    Enicepatide Dose Level 3 administered SC once weekly.

    Drug: Enicepatide

  • Experimental
    Arm 5: Enicepatide Dose Level 4

    Enicepatide Dose Level 4 administered SC once weekly.

    Drug: Enicepatide

  • Experimental
    Arm 6: Enicepatide Dose Level 5 (High)

    Enicepatide Dose Level 5 administered SC once weekly.

    Drug: Enicepatide

Interventions

  • DrugPlacebo

    Placebo will be volume- matched and administered subcutaneously (SC) once weekly.

  • Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

    Also known as: CT-388, RO7795068, RG6640

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight from Baseline to Week 48

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 48

    Time frame: Baseline and Week 48

  2. Absolute Change in Body Weight (kg) from Baseline to Week 48

    Time frame: Baseline to Week 48

  3. Percent Change in Body Weight from Baseline to Week 48 by Obesity Class

    Time frame: Baseline to Week 48

  4. Change in Body Mass Index (BMI) from Baseline to Week 48

    Time frame: Baseline to Week 48

  5. Change in Waist Circumference from Baseline to Week 48

    Time frame: Baseline to Week 48

  6. Change in Hip Circumference from Baseline to Week 48

    Time frame: Baseline to Week 48

  7. Change in Waist-to-Hip Ratio from Baseline to Week 48

    Time frame: Baseline to Week 48

  8. Change in Waist-to-Height Ratio from Baseline to Week 48

    Time frame: Baseline to Week 48

  9. Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 48

    Time frame: Baseline to Week 48

  10. Change in Fasting Plasma Glucose from Baseline to Week 48

    Time frame: Baseline to Week 48

  11. Change in Fasting Insulin from Baseline to Week 48

    Time frame: Baseline to Week 48

  12. Change in Fasting C-peptide from Baseline to Week 48

    Time frame: Baseline to Week 48

  13. Change in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from Baseline to Week 48

    Time frame: Baseline to Week 48

  14. Change in Quantitative Insulin Sensitivity Check Index (QUICKI) from Baseline to Week 48

    Time frame: Baseline to Week 48

  15. Percentage of Participants with Shift in Glycemic Status from Baseline to Week 48, Based on Fasting Plasma Glucose and HbA1c

    Time frame: Baseline and Week 48

07

Study locations

34 sites
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Central Alabama Research
    Homewood, Alabama 35209, United States
  • The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health
    Mesa, Arizona 85210, United States
  • Amicis Research Center - Anaheim
    Anaheim, California 92801, United States
  • Ark Clinical-Fountain Valley
    Fountain Valley, California 92708, United States
  • Ark Clinical Research - Long Beach
    Long Beach, California 90806, United States
  • Velocity Clinical Research - Los Angeles
    Los Angeles, California 90057, United States
  • Infinity Clinical Research
    Norco, California 92860, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Prospective Research Innovations Inc.
    Rancho Cucamonga, California 91730, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Amicis Research Center - West Hills
    West Hills, California 91307, United States
  • Tampa Bay Medical Research, Inc.
    Clearwater, Florida 33761, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • Neurobehavioral Research, Inc. (NBR)
    Cedarhurst, New York 11516, United States
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • Velocity Clinical Research - Cincinnati
    Cincinnati, Ohio 45242, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Tribe Clinical Research
    Greenville, South Carolina 29607, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
  • Apex Mobile Clinical Research
    Bellaire, Texas 77401, United States
  • Velocity Clinical Research - Dallas
    Dallas, Texas 75230, United States
  • FutureSearch Trials of Dallas, LLC
    Dallas, Texas 75231, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Elevate Clinical
    Seabrook, Texas 77586, United States
  • Impact Research Institute
    Waco, Texas 76710, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • National Clinical Research - Richmond, Inc
    Richmond, Virginia 23294, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Dec 2025, 15 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Jul 29, 2024
StartActual
Aug 16, 2024
Primary completionActual
Dec 8, 2025
CompletionActual
Dec 8, 2025
Results delay requested
Oct 1, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and registry dates
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06525935
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Aug 16, 2024
Primary completion
Dec 8, 2025
Completion
Dec 8, 2025
Last update
Oct 5, 2026

Study contacts

Clinical Trials
study director · Carmot Therapeutics, Inc., a Member of the Roche Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enicepatide

Start the discussion